All In Biotech

Drug Trial Radar · NCT03068455

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma

Last checked: Nov 20, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,844 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,844

Actual

Start

Apr 11, 2017

Primary completion

Jun 12, 2020

Study completion Feb 2, 2021

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV Melanoma

Conditions

  • Melanoma

Interventions

  • nivolumabBiological

    Specified Dose on Specified Days

  • ipilimumabBiological

    Specified Dose on Specified Days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free Survival (RFS) - All Randomized ParticipantsTime frame: From randomization to Primary Completion Date (up to approximately 3 years)
  2. Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level < 1%Time frame: From randomization to Primary Completion Date (up to approximately 3 years)

Locations

124 sites in 19 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center

    Tucson, Arizona

  • The Angeles Clinic & Research Institute

    Los Angeles, California

  • California Pacific Medical Center

    San Francisco, California

  • University Of Colorado

    Aurora, Colorado

  • Georgetown University Med Ctr

    Washington D.C., District of Columbia

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • UF Health Cancer Center at Orlando Health

    Orlando, Florida

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • University Of Chicago

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • Oncology Specialists, S.C.

    Park Ridge, Illinois

  • Mass General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University Of Michigan Health System

    Ann Arbor, Michigan

  • Virginia Piper Cancer Institute

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School Of Medicine

    St Louis, Missouri

  • NYU Langone Medical Center

    New York, New York

  • Memorial Sloan Kettering Nassau

    New York, New York

  • Carolinas Med Ctr

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Providence Cancer Center Oncology And Hematology Care

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • St. Luke's University Health Network

    Easton, Pennsylvania

  • Local Institution

    Nashville, Tennessee

  • Texas Oncology Sammons Cancer Center

    Dallas, Texas

  • Md Anderson Can Cnt

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • University Of Virginia Health System

    Charlottesville, Virginia

  • Inova Melanoma and Skin Cancer Center

    Fairfax, Virginia

  • University Of Washington Cancer Care Alliance

    Seattle, Washington

  • Local Institution

    North Sydney, New South Wales, Australia

  • Local Institution

    Waratah, New South Wales, Australia

  • Local Institution

    Westmead, New South Wales, Australia

  • Local Institution

    Greenslopes, Queensland, Australia

  • Local Institution

    Southport, Queensland, Australia

  • Local Institution

    Woolloongabba, Queensland, Australia

  • Local Institution

    Adelaide, South Australia, Australia

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.